Crypto Cloud Mining - 5% off! -- I'm making $50 per day on AUTO PILOT with Monero Cloud Mining on Genesis-Mining. Cloud mining works! Take 5% off your order with this link. 5% off Coupon code: 08FzhX

GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
GWPH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
-1.20%22.7114.1%$323.40m
SHPGShire PLC Sponsored ADR
-0.10%145.820.4%$199.66m
SAGESAGE Therapeutics, Inc.
0.08%168.4810.9%$102.40m
PRGOPerrigo Co. Plc
0.79%91.586.6%$77.15m
JAZZJazz Pharmaceuticals Plc
-0.06%149.712.2%$72.18m
UTHRUnited Therapeutics Corporation
3.85%140.3214.5%$60.87m
MNKMallinckrodt Plc
-3.72%22.2718.5%$60.77m
PTLAPortola Pharmaceuticals, Inc.
-0.84%49.757.8%$59.99m
CORTCorcept Therapeutics Incorporated.
4.13%22.195.5%$59.91m
GWPHGW Pharmaceuticals PLC Sponsored ADR
1.64%132.447.6%$49.47m
ENDPEndo International Plc
-4.00%7.698.9%$42.97m
ICPTIntercept Pharmaceuticals, Inc.
-0.49%52.7222.0%$42.74m
PCRXPacira Pharmaceuticals, Inc.
0.00%40.3010.7%$31.37m
ICLRICON Plc
0.53%112.884.1%$28.67m
MDCOMedicines Company
-1.17%25.3722.1%$26.75m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.